



**ADLER, ROBERT A.** Chief, Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center; Professor of Internal Medicine, Professor of Epidemiology and Community Health, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

Place of Birth: Somerville, New Jersey, USA

Education/Training/Positions: Franklin & Marshall College, Lancaster, Pennsylvania, 1963-65; BA, Johns Hopkins University, Baltimore, Maryland, 1967; MD, Johns Hopkins University School of Medicine, 1970; Intern and Resident, Internal Medicine, Johns Hopkins Hospital, 1970-1972; Fellow in Endocrinology, Massachusetts General Hospital, Boston, Massachusetts,

1972-73; Fellow in Endocrinology, Walter Reed Army Medical Center, Washington, DC, 1973-74; Assistant Chief, Endocrinology and Clinical Investigator, Fitzsimons Army Medical Center, Denver, Colorado, 1974-76; Clinical Instructor in Medicine, University of Colorado, Denver, Colorado, 1975-76; Assistant Professor and Associate Professor of Medicine, Dartmouth Medical School, Hanover, New Hampshire, 1976-84; Staff Endocrinologist, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, 1976-84; Consultant, Endocrinology, White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, 1976-84; Associate Professor and Professor of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, 1984-present; Professor of Epidemiology and Community Health, Virginia Commonwealth University School of Medicine, 2002-present; Assistant Chief, Endocrinology, McGuire Veterans Affairs Medical Center, Richmond, Virginia, 1984-1985; Chief, Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center, 1985-present

Honors/Awards: Teaching Award, Dartmouth Medical School, 1984; Teaching Award, Medical College of Virginia, Virginia Commonwealth University, 1998-1999; Irby-James Award for Excellence in Clinical Teaching, Virginia Commonwealth University, 2004

Editorial Duties/Peer Review Panels: Editorial Boards: *Journal of Clinical Endocrinology and Metabolism*, 1988-1992; *Journal of Clinical Densitometry*, 1997-present; *American Journal of Physiology*, Endocrinology Section, 1998-2001; Endocrine Research, 2008-present; *Journal of Bone and Mineral Research*, 2009-present; Editor, *Osteoporosis – Pathophysiology and Clinical Management*, 2nd Edition; Reviewer for 40 journals; Review Panels: Ad hoc reviewer, Department of Veterans Affairs Merit Review Program; March of Dimes Grant Program; American Federation for Aging Research; Spinal Cord Foundation; Jeffress Foundation;; MayDay Foundation; Department of Veterans Affairs Cooperative Studies Program; NIH Study Sections-Prevention of Osteoporosis, DDK-B Subcommittee, Skeletal Biology Structure and Regeneration, NIAMS Special Emphasis Panel; Ad hoc reviewer, NIH Skeletal Biology and Development and Disease, 2003-present; US Army Medical Research and Materiel Command Congressionally Directed Medical Research Program, 2009; Pre-Reviewer, Endocrinology Specialty Programs, Accreditation Council for Graduate Medical Education, 1994-1998; Endocrinology Subspecialty Appeals Panel, Accreditation Council for Graduate Medical Education, 2000-present; Osteoporosis Working Group, American Medical Association, Physician Consortium for Performance Improvement, 2006-2007; Chair, Department of Veterans Affairs Male Osteoporosis Technical Advisory Panel, 2007-present; Endocrinology and Diabetes Field Advisory Committee, Department of Veterans Affairs, 2008-present; American College of Rheumatology Glucocorticoid-Induced Osteoporosis Guidelines Task Force, 2009-present

Professional Societies: Membership: ASBMR, 1986-present; American Association for the Advancement of Science; Endocrine Society; Southern Society for Clinical Investigation; Pituitary Society; Fellow, American College of Physicians; International Bone and Mineral Society; International Society for Clinical Densitometry (ISCD); Scientific Advisory Committee, ISCD, 2003-present; Chair and member, ASBMR Professional Practice Committee, 2004-present; Ex Officio Member, ASBMR Science Policy Committee, 2007-present; Member, ASBMR Clinician Outreach Task Force, 2009; Co-Chair, Task Force on ASBMR-Industry Interactions, 2009; ASBMR Subtrochanteric Fracture Task Force 2009-present; ASBMR-NOF Liaison Group 2009-present; ASBMR representative to Endocrine Society Male Osteoporosis Guidelines Committee, 2009-present

Current Research: Screening for osteoporosis in men; bone mineral density testing in men; osteoporosis in men on androgen deprivation therapy for prostate cancer; muscle strength, balance, and osteoporosis in Parkinson's disease; interventions to improve management of glucocorticoid-induced osteoporosis; body composition changes and osteoporosis management in spinal cord injury; use of electronic medical records and decision support to improve osteoporosis management; male hormone replacement therapy; osteoporosis diagnosis and management in the Department of Veterans Affairs; pituitary dysfunction after traumatic brain injury.

Statement of Interest: I didn't become deeply interested in mineral metabolism until my basic research on prolactin led to studies of the association of hyperprolactinemia with osteoporosis. During a later career transition from basic to clinical research I found that little was known about osteoporosis in men, and I have devoted the last 15 years trying to add to our knowledge base. I founded a Metabolic Bone Disease Clinic at my Veterans Affairs Medical Center. As male osteoporosis became better recognized, the clinic has become very busy. It is a major teaching clinic, the only one where our students, residents, fellows, and pharmacy residents can learn about metabolic bone diseases. I continue to study male osteoporosis and was an invited speaker at

the recent NOF International Symposium on Osteoporosis. I serve as Chair of the Male Osteoporosis Technical Advisory Panel for the Department of Veterans Affairs. We have prepared an osteoporosis management algorithm that has been distributed to all V.A. medical centers.

Some years ago I applied for a position on the Professional Practice Committee, and after a few tries was nominated. As I became very involved with the work of the committee, I eventually became its chair, a job that has carried significant responsibility and a lot of work – but it has also been a great pleasure and privilege. The PPC has dealt with many topics such as the new NOF Guidelines, complications of osteoporosis treatment, reimbursement for DXA and vitamin D measurements, performance measures, and the FRAX. The discussions have been intellectually stimulating, and the PPC has contributed to assuring quality in medical practice. I have had the privilege of moderating important clinical sessions at the annual meeting, based on contentious clinical issues – and hope to do so again in 2010. My status as a salaried V.A. employee gives me a more objective perspective on such clinical issues as DXA reimbursement. I have read 10,000 DXAs but receive no direct compensation for it. Thus on reimbursement issues, I have no potential conflicts. I have both investigator-initiated and pharmaceutical research funds. I continue to consult for a few companies because my expertise can be used to further patient care this way. I have been on speakers' bureaus, but I just turned one offer down because there was no "academic freedom." All of my talks could be given at CME sessions.

Serving on Council would utilize my experience as PPC Chair and help with continuing and future issues. As US medicine is "reformed," there will be many challenges. We can learn from other countries, from the "socialized" system I have worked in, and from the many PPC discussions. It would be a great honor to continue my work this way, based on basic science, clinical research, clinical practice, teaching, and committee experience. I have enjoyed and learned much working with my ASBMR colleagues and the ASBMR staff. I believe that I can make further contributions to the organization and to medical science.

Disclosures: Amgen 1; Eli Lilly and Co. 1, 2; Genentech 1; GTx, Inc. 2; Merck & Co., Inc. 2; Novartis 1, 3; Procter & Gamble 1; ISCD 6 (Scientific Advisory Committee); *Endocrine Research* 6 (Editorial Board); *Journal of Clinical Densitometry* 6 (Editorial Board)

*The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.*

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*